EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Multizentrische StudieRandomisierte kontrollierte Studie

Engasertib versus Placebo for Bleeding in Hereditary Hemorrhagic Telangiectasia

Hanny Al-Samkari iD, Josefien Hessels, Antoni Riera-Mestre iD, Sophie Dupuis-Girod, Thibaut Van Zele, Vicente Gómez Del Olmo, Pamela G Hodges, Raquel Torres-Iglesias, Roberto Bertè, Pierre Saint-Mezard, Hedvika Lazar, Nicholas Benedict und 5 weitere

New England Journal of Medicine · 27.11.2025 · 393 (21) · 2131-2141

DOI: 10.1056/nejmoa2504411 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift New England Journal of Medicine, erschienen am 27.11.2025. Verfasst von Hanny Al-Samkari und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Massachusetts General Hospital, Harvard Medical School, Boston. Hauptthemen laut MEDLINE: Epistaxis, Telangiectasia, Hereditary Hemorrhagic, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-akt. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Vaderis Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Hereditary hemorrhagic telangiectasia (HHT) can cause recurrent, severe epistaxis, as well as anemia and reduced quality of life. The disease remains without licensed therapies worldwide. METHODS: In this proof-of-concept, multicenter, double-blind, placebo-controlled trial, we evaluated the safety and efficacy of oral engasertib, a new, allosteric, selective AKT inhibitor, in patients with HHT. Patients were randomly assigned in a 1:1:1 ratio to receive engasertib at a dose of 30 mg, engasertib at a dose of 40 mg, or placebo once daily for 12 weeks. The primary outcomes were the frequency and severity of adverse events. Key secondary outcomes included the frequency and duration of epistaxis. An open-label extension is ongoing. RESULTS: A total of 75 patients were assigned to 30-mg engasertib (24 patients), 40-mg engasertib (25 patients), or placebo (26 patients). Among the patients who received at least one dose of the trial regimen, the most common on-target adverse events associated with engasertib included mild-to-moderate rash (5 patients [21%] in the 30-mg engasertib group, 10 [42%] in the 40-mg engasertib group, and 2 [8%] in the placebo group) and mild-to-moderate hyperglycemia (3 patients [12%] in the 40-mg engasertib group and no patients in the other two groups), which were reversible. The incidence of serious adverse events in each of the two engasertib groups was similar to that in the placebo group. From baseline to week 12, the mean (±SD) decrease in epistaxis frequency was 26.5±26.5% with 30-mg engasertib, 27.8±35.1% with 40-mg engasertib, and 18.0±36.0% with placebo; the mean decrease in epistaxis duration was 29.9±53.2%, 41.4±41.0%, and 23.8±53.4%, respectively. CONCLUSIONS: The safety profile of engasertib was similar to that of placebo except for mild-to-moderate rash, which resolved in most patients who continued to receive the drug. Engasertib treatment was associated with decreases in epistaxis frequency and duration. (Funded by Vaderis Therapeutics; ClinicalTrials.gov number, NCT05406362.).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EpistaxisTelangiectasia, Hereditary HemorrhagicProtein Kinase InhibitorsProto-Oncogene Proteins c-aktAdultAgedFemaleHumansMaleMiddle AgedAdministration, OralDouble-Blind MethodProof of Concept StudyAllosteric RegulationIncidenceTreatment Outcome

Substanzen

Protein Kinase InhibitorsAKT1 protein, humanAKT2 protein, humanProto-Oncogene Proteins c-akt

Autor:innen und Institutionen

  • Division of Hematology-Oncology, Massachusetts General Hospital, Harvard Medical School, Boston.
  • Department of Pulmonology, St. Antonius Hospital, Nieuwegein, the Netherlands.
  • Department of Internal Medicine, Hospital Universitari de Bellvitge-Institut d'Investigació Biomèdica de Bellvitge, L'Hospitalet de Llobregat, Spain.
  • Genetic Department, Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Bron, France.
  • Biosanté Unit 1292, Grenoble Alpes University, INSERM, Commissariat à L'Énergie Atomique et aux Énergies Alternatives, Grenoble, France.
  • Department of Otorhinolaryngology, Ghent University Hospital, Ghent, Belgium.

ORCID-Profile: Hanny Al-Samkari, Antoni Riera-Mestre, Corrado Bernasconi

Förderung

  • Vaderis Therapeutics

Zitieren

APA

Al-Samkari, H., Hessels, J., Riera-Mestre, A., Dupuis-Girod, S., Van Zele, T., Gómez Del Olmo, V., Hodges, P. G., Torres-Iglesias, R., Bertè, R., Saint-Mezard, P., Lazar, H., Benedict, N., Barker, D., Bernasconi, C., Picard, D., Buscarini, E., & Mager, H. J. (2025). Engasertib versus Placebo for Bleeding in Hereditary Hemorrhagic Telangiectasia. New England Journal of Medicine, 393(21), 2131-2141. https://doi.org/10.1056/nejmoa2504411

Vancouver

Al-Samkari H, Hessels J, Riera-Mestre A, Dupuis-Girod S, Van Zele T, Gómez Del Olmo V, et al. Engasertib versus Placebo for Bleeding in Hereditary Hemorrhagic Telangiectasia. New England Journal of Medicine. 2025;393(21):2131-2141. doi:10.1056/nejmoa2504411

BibTeX
@article{AlSamkari2025,
  author = {Al-Samkari, Hanny and Hessels, Josefien and Riera-Mestre, Antoni and Dupuis-Girod, Sophie and Van Zele, Thibaut and Gómez Del Olmo, Vicente and Hodges, Pamela G and Torres-Iglesias, Raquel and Bertè, Roberto and Saint-Mezard, Pierre and Lazar, Hedvika and Benedict, Nicholas and Barker, Debra and Bernasconi, Corrado and Picard, Damien and Buscarini, Elisabetta and Mager, Hans-Jurgen},
  title = {Engasertib versus Placebo for Bleeding in Hereditary Hemorrhagic Telangiectasia},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {393},
  number = {21},
  pages = {2131--2141},
  doi = {10.1056/nejmoa2504411}
}
Kostenlos starten →